Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
News|Articles|September 8, 2026
ESC 2026 Recap: 5 Practice-Changing Trials to Know
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.
Advertisement
Advertisement
The
Related to this article
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Advertisement
Advertisement